US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SDEV $7.48 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% TSLA $370.59 ▲+0.00%
FinancialContent

Articles published by Monopar Therapeutics Inc.

< Previous 1 2 Next >
News headline image
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
News headline image
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
Tickers MNPR
< Previous 1 2 Next >